2023
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2
Zeidan A, Giagounidis A, Sekeres M, Xiao Z, Sanz G, Van Hoef M, Ma F, Hertle S, Santini V. STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future Oncology 2023, 19: 631-642. PMID: 37083373, DOI: 10.2217/fon-2022-1237.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHigh-risk myelodysplastic syndromeChronic myelomonocytic leukemiaMyelodysplastic syndromeCMML-2Tim-3Hematopoietic stem cell transplantationT-cell immunoglobulin domainMucin domain 3Risk myelodysplastic syndromesPhase III trialsStem cell transplantationLeukemic stem cellsFavorable tolerabilityIII trialsNovel immunotherapiesPoor outcomeCell transplantationLeukemic blastsClinical trialsNovel therapiesMyelomonocytic leukemiaDurable benefitImmune systemMyeloid malignanciesMeaningful improvements
2021
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia
Xiao W, Chan A, Waarts M, Mishra T, Liu Y, Cai S, Yao J, Gao Q, Bowman R, Koche R, Csete I, DelGaudio N, Derkach A, Baik J, Yanis S, Famulare C, Patel M, Arcila M, Stahl M, Rampal R, Tallman M, Zhang Y, Dogan A, Goldberg A, Roshal M, Levine R. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood 2021, 137: 1377-1391. PMID: 32871587, PMCID: PMC7955409, DOI: 10.1182/blood.2020007897.Peer-Reviewed Original ResearchConceptsBlastic plasmacytoid dendritic cell neoplasmPlasmacytoid dendritic cellsAcute myeloid leukemiaPDC expansionPDC-AMLRUNX1-mutated acute myeloid leukemiaRUNX1 mutationsLeukemic blastsDendritic cellsMyeloid leukemiaCross-lineage antigen expressionPlasmacytoid dendritic cell differentiationPlasmacytoid dendritic cell neoplasmPatient-derived xenograft modelsAcute myeloid leukemia casesMature plasmacytoid dendritic cellsPlasmacytoid dendritic cell precursorsDendritic cell expansionChronic myelomonocytic leukemiaDendritic cell neoplasmPotential treatment approachTranscriptional programsCD123 targetingLeukemic burdenCell neoplasms
2020
Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?
Bewersdorf JP, Zeidan AM. Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments? Cells 2020, 9: 2310. PMID: 33080779, PMCID: PMC7603052, DOI: 10.3390/cells9102310.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTumor lysis syndromeAcute myeloid leukemiaLeukemic blastsMyeloid leukemiaCell adhesion moleculeAggressive intravenous fluid hydrationWhite blood cell countEndothelial cellsAdhesion moleculesDevelopment of leukostasisIntravenous fluid hydrationManagement of DICMainstay of therapyLife-threatening complicationsBlood cell countLeukemic stem cell survivalBone marrow microenvironmentIntensive chemotherapyIntravascular coagulationLysis syndromeFluid hydrationSupportive treatmentAdverse prognosisAML patientsInflammatory cytokines
2018
Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
Uy N, Nadeau M, Stahl M, Zeidan AM. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia. Journal Of Blood Medicine 2018, 9: 67-74. PMID: 29713210, PMCID: PMC5908210, DOI: 10.2147/jbm.s136575.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChemotherapy-based approachesInotuzumab ozogamicinAcute lymphoblastic leukemiaB-ALLLymphoblastic leukemiaChimeric antigen receptor (CAR) T-cell productBispecific T-cell engager blinatumomabAcute B-cell lymphoblastic leukemiaPhiladelphia chromosome-positive diseaseSecond-line salvage therapyB-cell lymphoblastic leukemiaExcellent clinical activityT-cell productsRelapsed B-ALLCD22 monoclonal antibodySalvage therapyAdult patientsSupportive careCell transplantationLeukemic blastsSuperior survivalClinical trialsClinical activityOzogamicinClinical data
2005
Methods of dendritic cell preparation for acute lymphoblastic leukemia immunotherapy in children
Pospíšilová D, Borovičková J, Rožková D, Stary J, Seifertová D, Tobiásová Z, Špišek R, Bartůnková J. Methods of dendritic cell preparation for acute lymphoblastic leukemia immunotherapy in children. Medical Oncology 2005, 22: 79-88. PMID: 15750200, DOI: 10.1385/mo:22:1:079.Peer-Reviewed Original ResearchConceptsDendritic cellsPeripheral mononuclear cellsAcute lymphoblastic leukemiaMononuclear cellsCostimulatory moleculesBone marrow leukemic blastsPreparation of DCsPeripheral blood mononuclear cellsDendritic cell preparationsSpecific cytotoxic lymphocytesTime of remissionTime of diagnosisMature dendritic cellsBlood mononuclear cellsEfficiency of immunotherapyAutologous lymphocyte proliferationHematopoietic malignant cellsEvidence of inductionInduction chemotherapyBM blastsPediatric patientsCell immunotherapyB-ALLLymphoblastic leukemiaLeukemic blasts
1996
Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.
Wright D, Boosalis M, Waraska K, Oshry L, Weintraub L, Vosburgh E. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis. Anticancer Research 1996, 16: 3349-51. PMID: 9042310.Peer-Reviewed Original ResearchConceptsLeukemic blastsBlast crisisMRNA expressionCML-BC patientsPhase II trialBlood of patientsCycle-active agentsChronic myelogenous leukemiaDays of treatmentCML blast crisisHematologic remissionII trialTrial patientsHematologic responseTiazofurin treatmentWBC countIMP dehydrogenase activityCML-BCPartial clearanceMyelogenous leukemiaLeukemic clonePatientsNeoplastic cellsSequential coursesProliferative activity
1992
A gamma delta+ T-cell leukemia bearing a novel t(8;14)(q24;q11) translocation demonstrates spontaneous in vitro natural killer-like activity.
Maziarz R, Arceci R, Bernstein S, Frazier L, Smith B, Kasai M, Tantravahi R, Strominger J. A gamma delta+ T-cell leukemia bearing a novel t(8;14)(q24;q11) translocation demonstrates spontaneous in vitro natural killer-like activity. Blood 1992, 79: 1523-31. PMID: 1532137, DOI: 10.1182/blood.v79.6.1523.bloodjournal7961523.Peer-Reviewed Original ResearchConceptsNatural killer-like activityT-cell leukemiaClinical conditionsNon-major histocompatibility complexPatient's clinical conditionGamma delta TCRTumor cell lysisFresh leukemic blastsDelta 1 gene segmentIntracellular calcium fluxGamma delta lineageT cell linesHuman T-cell leukemiaLeukemic blastsCytolytic activityDelta TCRLeukemia blastsC-myc proto-oncogene locusCalcium fluxCell surface analysisHistocompatibility complexDelta lineageLeukemiaLeukemia cellsProto-oncogene locusA γδ+ T-Cell Leukemia Bearing a Novel t(8;14)(q24;q11) Translocation Demonstrates Spontaneous In Vitro Natural Killer-Like Activity
Maziarz R, Arced R, Bernstein S, Frazier L, Smith B, Kasai M, Tantravahi R, Strominger J. A γδ+ T-Cell Leukemia Bearing a Novel t(8;14)(q24;q11) Translocation Demonstrates Spontaneous In Vitro Natural Killer-Like Activity. Blood 1992, 79: 1523-1531. DOI: 10.1182/blood.v79.6.1523.1523.Peer-Reviewed Original ResearchNatural killer-like activityT-cell leukemiaClinical conditionsNon-major histocompatibility complexPatient's clinical conditionGamma delta TCRTumor cell lysisFresh leukemic blastsDelta 1 gene segmentIntracellular calcium fluxGamma delta lineageT cell linesHuman T-cell leukemiaLeukemic blastsCytolytic activityDelta TCRLeukemia blastsC-myc proto-oncogene locusCalcium fluxCell surface analysisHistocompatibility complexDelta lineageLeukemiaLeukemia cellsProto-oncogene locus
1990
RAS gene product expression in blood and marrow smears of patients with acute leukemia: Importance of fixation
Needleman S, Cimino E, Mane S, Gutheil J, Kapil V, Chana G. RAS gene product expression in blood and marrow smears of patients with acute leukemia: Importance of fixation. Pathology 1990, 22: 77-81. PMID: 2235101, DOI: 10.3109/00313029009063784.Peer-Reviewed Original ResearchConceptsAcute non-lymphoblastic leukemiaP21 expressionAcute leukemiaMarrow aspiratesNon-lymphoblastic leukemiaNon-malignant diseasesHigh p21 expressionRas p21 expressionHistologic anaplasiaMost patientsRegional lymphLeukemic blastsProstate cancerBreast cancerGene product expressionPlasma cellsMarrow smearsNormal volunteersBlast cellsPatientsMyeloid cellsCodon 12Importance of fixationBlood smearsHuman malignancies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply